The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Enhanced Immune Response and Protective Effects of Nano-chitosan-based DNA Vaccine Encoding T Cell Epitopes of Esat-6 and FL against Mycobacterium Tuberculosis Infection
Open accessAbstract
Development of a novel and effective vaccine against Mycobacterium tuberculosis (M.tb) is a challenging for preventing TB infection. In this study, a novel nanoparticle-based recombinant DNA vaccine was developed, which contains Esat-6 three T cell epitopes (Esat-6/3e) and fms-like tyrosine kinase 3 ligand (FL) genes (termed Esat-6/3e-FL), and was enveloped with chitosan (CS) nanoparticles (nano-chitosan). The immunologic and protective efficacy of the nano-chitosan-based DNA vaccine (termed nano-Esat-6/3e-FL) was assessed in C57BL/6 mice after intramuscular prime vaccination with the plasmids DNA and nasal boost with the Esat-6/3e peptides. The results showed that the immunized mice remarkably elicited enhanced T cell responses and protection against M.tb H37Rv challenge. These findings indicate that the nano-chitosan can significantly elevate the immunologic and protective effects of the DNA vaccine, and the nano-Esat-6/3e-FL is a useful vaccine for preventing M.tb infection in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A nano-chitosan-based recombinant DNA vaccine elevated the immunologic and protective effects against TB in a mouse model 136”
From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
DNA Vaccines: Immunology, Application, and Optimization
Gurunathan, S., Klinman, D. M., & Seder, R. A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.927 · Cited by 1,198
Huang, M., Khor, E., & Lim, L. Y. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000016249.52831.a5 · Cited by 853
Chitosan as a novel nasal delivery system for vaccines
Illum, L., Jabbal‐Gill, I., Hinchcliffe, M., Fisher, A. N., & Davis, S. S. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00171-5 · Cited by 764
The Population Dynamics and Control of Tuberculosis
Dye, C., & Williams, B. G. (2010) · Science · doi:10.1126/science.1185449 · Cited by 609
DNA-polycation nanospheres as non-viral gene delivery vehicles
Leong, K. W., Mao, H., Truong-Le, V. L., Roy, K., Walsh, S. M., & August, J. T. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00252-6 · Cited by 538
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice
Vila, A., Sánchez, A., Janes, K. A., Behrens, I., Kissel, T., Jato, J. L. V., & Alonso, M. J. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2003.09.006 · Cited by 449
Behrens, I., Pena, A. I. V., Alonso, M. J., & Kissel, T. (2002) · Pharmaceutical Research · doi:10.1023/a:1019854327540 · Cited by 377
ESAT-6 Subunit Vaccination against Mycobacterium tuberculosis
Brandt, L., Elhay, M. J., Rosenkrands, I., Lindblad, E. B., & Andersen, P. L. (2000) · Infection and Immunity · doi:10.1128/iai.68.2.791-795.2000 · Cited by 336
Epitope-based vaccines: an update on epitope identification, vaccine design and delivery
Sette, A., & Fikes, J. D. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00083-9 · Cited by 323
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–108 of 108
- Retracted
A Review of Comparative Strategies Against Pneumonia: Vaccine and Antibiotic Resistance Mitigation
Ahmed, M., Ahmad, M., Hussain, H., Rizwan, Nadeem, Z., Mustehsan, M., Sami, A., Kanwal, H., Akbar, S. S., Ali, M., et al. (2025) · The Open Microbiology Journal · doi:10.2174/0118742858424997251105071208 · Cited by 1
Nanotechnology-based drug delivery for combating SARS-CoV-2 variants
Yousfi, R. E., Sayah, O., Dalli, M., Belkadi, M. C., Maleb, A., & Idrissi, A. E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33002-5.00021-x
Maurya, S. K., Aqdas, M., Das, D. K., Singh, S., Nadeem, S., Kaur, G., & Agrewala, J. N. (2020) · Figshare · doi:10.6084/m9.figshare.12972094
Rajadas, S. E., Sounderrajan, V., Prabhakaran, R. A., Agrawal, R., Jeyadoss, L., Rajan, M., Parthasarathy, K., & Harshavardhan, S. (2024) · Figshare · doi:10.6084/m9.figshare.26735031
Rajadas, S. E., Sounderrajan, V., Prabhakaran, R. A., Agrawal, R., Jeyadoss, L., Rajan, M., Parthasarathy, K., & Harshavardhan, S. (2024) · Figshare · doi:10.6084/m9.figshare.26735028
Rajadas, S. E., Sounderrajan, V., Prabhakaran, R. A., Agrawal, R., Jeyadoss, L., Rajan, M., Parthasarathy, K., & Harshavardhan, S. (2024) · Figshare · doi:10.6084/m9.figshare.26735022
Rajadas, S. E., Sounderrajan, V., Prabhakaran, R. A., Agrawal, R., Jeyadoss, L., Rajan, M., Parthasarathy, K., & Harshavardhan, S. (2024) · Figshare · doi:10.6084/m9.figshare.26735025
Metadata
- Authors
- Feng, G., Jiang, Q., Xia, M., Lu, Y., Qiu, W., Zhao, D., Lu, L., Peng, G., & Wang, Y.
- Affiliations
- Nanjing Medical University (CN)
- University of Hong Kong (HK)
- Saint Louis University (US)
- Corresponding author
- Wang, Yingwei
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-04-23
- Volume
- 8
- Issue
- 4
- Pages
- e61135
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3634041
- OpenAlex
- W1968939141
- Cited by
- 108
- References
- 53
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 10 · 2023: 9 · 2022: 16 · 2021: 12 · 2020: 12 · 2019: 5 · 2018: 7 · 2017: 5 · 2016: 8 · 2015: 8 · 2014: 6 · 2013: 5
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-05-08)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
- Funders
- Government of Jiangsu Province
- Southeast University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- Mycobacterium tuberculosis, tuberculosis vaccine, DNA vaccine, chitosan nanoparticles, ESAT-6, T cell epitopes, FMS-like tyrosine kinase 3 ligand, T cell response, protective immunity
- MeSH terms
- T-bet Transcription Factor, Amino Acid Sequence, Animals, Antigens, Bacterial, Bacterial Proteins, Cell Count, Female, Gene Expression Regulation, Immunization, Interferon-gamma, Ligands, Mice, Inbred C57BL, Molecular Sequence Data, Mycobacterium tuberculosis, Particle Size, Recombinant Proteins, Spleen, T-Lymphocytes, Cytotoxic, Transfection, Tuberculosis, Cytokines, Epitopes, T-Lymphocyte, Vaccines, DNA, T-Box Domain Proteins, Chitosan, Cell Proliferation, GATA3 Transcription Factor, Mice, fms-Like Tyrosine Kinase 3, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
